HRP20110349T1 - Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma - Google Patents
Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma Download PDFInfo
- Publication number
- HRP20110349T1 HRP20110349T1 HR20110349T HRP20110349T HRP20110349T1 HR P20110349 T1 HRP20110349 T1 HR P20110349T1 HR 20110349 T HR20110349 T HR 20110349T HR P20110349 T HRP20110349 T HR P20110349T HR P20110349 T1 HRP20110349 T1 HR P20110349T1
- Authority
- HR
- Croatia
- Prior art keywords
- sulfonamide compound
- cancer
- treatment
- substance
- inhibitory effect
- Prior art date
Links
- 229940124530 sulfonamide Drugs 0.000 title claims abstract 12
- -1 sulfonamide compound Chemical class 0.000 title claims abstract 12
- 206010028980 Neoplasm Diseases 0.000 title claims 9
- 201000011510 cancer Diseases 0.000 title claims 9
- 230000002401 inhibitory effect Effects 0.000 claims abstract 11
- 239000000126 substance Substances 0.000 claims abstract 11
- LWGUASZLXHYWIV-UHFFFAOYSA-N 3-cyano-n-(3-cyano-4-methyl-1h-indol-7-yl)benzenesulfonamide Chemical compound C1=2NC=C(C#N)C=2C(C)=CC=C1NS(=O)(=O)C1=CC=CC(C#N)=C1 LWGUASZLXHYWIV-UHFFFAOYSA-N 0.000 claims abstract 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims abstract 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract 2
- 229960005395 cetuximab Drugs 0.000 claims abstract 2
- 229960001433 erlotinib Drugs 0.000 claims abstract 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960002584 gefitinib Drugs 0.000 claims abstract 2
- SETFNECMODOHTO-UHFFFAOYSA-N indisulam Chemical compound C1=CC(S(=O)(=O)N)=CC=C1S(=O)(=O)NC1=CC=CC2=C1NC=C2Cl SETFNECMODOHTO-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000012453 solvate Substances 0.000 claims abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 238000009472 formulation Methods 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Farmaceutski pripravak obuhvaća spoj sulfonamida u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF, naznačen time, što spoj sulfonamida je: N-(3-klor-1H-indol-7-il)-4-sulfamoilbenzensulfonamid,N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzensulfonamid, ili njegova farmakološki prihvatljiva sol ili njegov solvat, i pri čemu supstanca koja ima inhibicijsko djelovanje EGF je gefitinib, erlotinib ili cetuksimab. Patent sadrži još 9 patentnih zahtjeva.
Claims (10)
1. Farmaceutski pripravak obuhvaća spoj sulfonamida u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF, naznačen time, što spoj sulfonamida je:
N-(3-klor-1H-indol-7-il)-4-sulfamoilbenzensulfonamid,N-(3-cijano-4-metil-1H-indol-7-il)-3-cijanobenzensulfonamid, ili njegova farmakološki prihvatljiva sol ili njegov solvat,
i pri čemu supstanca koja ima inhibicijsko djelovanje EGF je gefitinib, erlotinib ili cetuksimab.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time, što se farmaceutski pripravak koristi za liječenje karcinoma.
3. Pribor, naznačen time, što obuhvaća skup formulacije koja sadrži spoj sulfonamida definiran u zahtjevu 1 i formulacije koja sadrži supstancu koja ima inhibicijsko djelovanje EGF definiranu u zahtjevu 1.
4. Pribor prema zahtjevu 4, naznačen time, što je za uporabu u liječenju karcinoma.
5. Upotreba spoja sulfonamida definiranog u zahtjevu 1 naznačena time, što za proizvodnju farmaceutskog pripravka za upotrebu u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF definiranom u zahtjevu 1 za liječenje karcinoma.
6. Upotreba supstance koja ima inhibicijsko djelovanje EGF definirano u zahtjevu 1 naznačena time, što za proizvodnju farmaceutskog pripravka za upotrebu u kombinaciji sa spojem sulfonamida definirano u zahtjevu 1 za liječenje karcinoma.
7. Spoj sulfonamida definiran u zahtjevu 1 naznačen time, što za upotrebu u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF definiranom u zahtjevu 1 za liječenje karcinoma.
8. Supstanca koja ima inhibicijsko djelovanje EGF definirana u zahtjevu 1 naznačena time, što za upotrebu u kombinaciji sa spojem sulfonamida definiranim u zahtjevu 1 za liječenje karcinoma.
9. Farmaceutski pripravak obuhvaća spoj sulfonamida definiran u zahtjevu 1 naznačen time, što za upotrebu u kombinaciji sa supstancom koja ima inhibicijsko djelovanje EGF definiranom u zahtjevu 1 za liječenje karcinoma.
10. Farmaceutski pripravak obuhvaća supstancu koja ima inhibicijsko djelovanje EGF definiranu u zahtjevu 1 naznačen time, što za upotrebu u kombinaciji sa spojem sulfonamida definiranim u zahtjevu 1 za liječenje karcinoma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005054111 | 2005-02-28 | ||
| PCT/JP2006/304218 WO2006090930A1 (ja) | 2005-02-28 | 2006-02-28 | スルホンアミド化合物の新規併用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110349T1 true HRP20110349T1 (hr) | 2011-07-31 |
Family
ID=36927547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110349T HRP20110349T1 (hr) | 2005-02-28 | 2011-05-11 | Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20090047278A1 (hr) |
| EP (1) | EP1859793B1 (hr) |
| JP (1) | JPWO2006090930A1 (hr) |
| KR (1) | KR20070108270A (hr) |
| CN (1) | CN101163468A (hr) |
| AU (1) | AU2006217692A1 (hr) |
| CA (1) | CA2599115A1 (hr) |
| CY (1) | CY1111579T1 (hr) |
| DE (1) | DE602006021401D1 (hr) |
| DK (1) | DK1859793T3 (hr) |
| ES (1) | ES2362898T3 (hr) |
| HR (1) | HRP20110349T1 (hr) |
| ME (1) | ME01222B (hr) |
| PL (1) | PL1859793T3 (hr) |
| PT (1) | PT1859793E (hr) |
| RS (1) | RS51821B (hr) |
| SI (1) | SI1859793T1 (hr) |
| WO (1) | WO2006090930A1 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) * | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
| US7683172B2 (en) * | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| WO2006030826A1 (ja) | 2004-09-17 | 2006-03-23 | Eisai R & D Management Co., Ltd. | 医薬組成物 |
| AU2006210572B2 (en) | 2005-02-03 | 2011-08-04 | The General Hospital Corporation | Method for treating gefitinib resistant cancer |
| EP1859804B1 (en) * | 2005-02-10 | 2016-12-07 | Oncolys BioPharma, Inc. | Anticancer agent combination therapy |
| WO2006090931A1 (ja) * | 2005-02-28 | 2006-08-31 | Eisai R & D Management Co., Ltd. | スルホンアミド化合物の抗癌剤との新規併用 |
| EP1925676A4 (en) | 2005-08-02 | 2010-11-10 | Eisai R&D Man Co Ltd | TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR |
| CN102716490A (zh) * | 2005-09-01 | 2012-10-10 | 卫材R&D管理有限公司 | 药物组合物的崩解性的改善方法 |
| AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
| JPWO2007052849A1 (ja) | 2005-11-07 | 2009-04-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用 |
| US20090247576A1 (en) * | 2005-11-22 | 2009-10-01 | Eisai R & D Management Co., Ltd. | Anti-tumor agent for multiple myeloma |
| WO2007136103A1 (ja) * | 2006-05-18 | 2007-11-29 | Eisai R & D Management Co., Ltd. | 甲状腺癌に対する抗腫瘍剤 |
| EP2044939A1 (en) * | 2006-06-29 | 2009-04-08 | Eisai R&D Management Co., Ltd. | Therapeutic agent for liver fibrosis |
| WO2008026748A1 (fr) * | 2006-08-28 | 2008-03-06 | Eisai R & D Management Co., Ltd. | Agent antitumoral pour cancer gastrique non différencié |
| AU2008205847A1 (en) * | 2007-01-19 | 2008-07-24 | Eisai R & D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| CN101600694A (zh) * | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CA2713930A1 (en) * | 2008-01-29 | 2009-08-06 | Eisai R & D Management Co., Ltd. | Combined use of angiogenesis inhibitor and taxane |
| KR20180128078A (ko) | 2008-06-17 | 2018-11-30 | 와이어쓰 엘엘씨 | Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물 |
| NZ590464A (en) | 2008-08-04 | 2012-10-26 | Wyeth Llc | Antineoplastic combinations of the 4-anilino-3-cyanoquinoline neratinib and capecitabine |
| HUE061640T2 (hu) | 2009-04-06 | 2023-07-28 | Wyeth Llc | Gyógykezelési rendszer mellrákhoz neratinib alkalmazásával |
| MX2012014776A (es) | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| KR20150098605A (ko) | 2012-12-21 | 2015-08-28 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴놀린 유도체의 비정질 형태 및 그의 제조방법 |
| JP6411379B2 (ja) | 2013-05-14 | 2018-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー |
| ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CU24558B1 (es) * | 2017-11-28 | 2021-12-08 | Ct Inmunologia Molecular | Anticuerpos monoclonales que reconocen al receptor del factor de crecimiento epidérmico y sus fragmentos derivados |
| AU2019211383A1 (en) * | 2018-01-25 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Sulfonamide derivatives for protein degradation |
| EP3781561B1 (en) | 2018-04-18 | 2024-03-13 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2021151974A1 (en) | 2020-01-28 | 2021-08-05 | Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis | Interfering with mrna splicing to enhance response to checkpoint immunotherapies. |
| US20230190707A1 (en) * | 2020-05-15 | 2023-06-22 | Fred Hutchinson Cancer Center | Compositions and methods for enhancing cancer immunotherapy |
| CN113679720B (zh) * | 2020-05-19 | 2024-09-27 | 苏中药业集团股份有限公司 | 一种取代丁烯酰胺联合铂类化合物的药物组合物及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| JPS5857710A (ja) | 1981-09-30 | 1983-04-06 | Matsushita Electric Works Ltd | コイル |
| DE3474040D1 (en) * | 1984-11-22 | 1988-10-20 | Holsten Brauerei Ag | Beer and process for its preparation |
| GR862353B (en) * | 1985-09-23 | 1987-01-19 | Lilly Co Eli | Anti-tumor method and compounds |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
| JP3545461B2 (ja) * | 1993-09-10 | 2004-07-21 | エーザイ株式会社 | 二環式ヘテロ環含有スルホンアミド誘導体 |
| HU224069B1 (hu) * | 1993-09-10 | 2005-05-30 | Eisai Co. Ltd. | Heterobiciklusos szulfonamid-származékok, eljárás előállításukra, ezeket hatóanyagként tartalmazó gyógyászati készítmények, valamint alkalmazásuk gyógyászati készítmények előállítására |
| EP3103799B1 (en) | 1995-03-30 | 2018-06-06 | OSI Pharmaceuticals, LLC | Quinazoline derivatives |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| JP2000247949A (ja) | 1999-02-26 | 2000-09-12 | Eisai Co Ltd | スルホンアミド含有インドール化合物 |
| YU13200A (sh) * | 1999-03-31 | 2002-10-18 | Pfizer Products Inc. | Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja |
| WO2001097843A2 (en) * | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
| MXPA03011197A (es) * | 2001-06-06 | 2004-02-26 | Lilly Co Eli | Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales. |
| DE10133394A1 (de) * | 2001-07-13 | 2003-01-30 | Merck Patent Gmbh | Flüssige Formulierung enthaltend Cetuximab |
| TWI281916B (en) | 2001-10-25 | 2007-06-01 | Lilly Co Eli | Antitumor compounds and methods |
| WO2003074045A1 (fr) * | 2002-03-05 | 2003-09-12 | Eisai Co., Ltd. | Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese |
| TWI283243B (en) * | 2002-09-19 | 2007-07-01 | Schering Corp | Novel pyrazolopyridines as cyclin dependent kinase inhibitors |
| JP3785390B2 (ja) | 2002-09-24 | 2006-06-14 | 平野整機工業株式会社 | 自転車後輪駆動装置及び自転車 |
| US20040209930A1 (en) * | 2002-10-02 | 2004-10-21 | Carboni Joan M. | Synergistic methods and compositions for treating cancer |
| US7378423B2 (en) * | 2004-06-11 | 2008-05-27 | Japan Tobacco Inc. | Pyrimidine compound and medical use thereof |
| EP2364699A1 (en) * | 2004-09-13 | 2011-09-14 | Eisai R&D Management Co., Ltd. | Joint use of sulfonamide based compound with angiogenesis inhibitor |
-
2006
- 2006-02-28 SI SI200631061T patent/SI1859793T1/sl unknown
- 2006-02-28 KR KR1020077022300A patent/KR20070108270A/ko not_active Application Discontinuation
- 2006-02-28 CA CA002599115A patent/CA2599115A1/en not_active Abandoned
- 2006-02-28 PL PL06715261T patent/PL1859793T3/pl unknown
- 2006-02-28 DK DK06715261.1T patent/DK1859793T3/da active
- 2006-02-28 EP EP06715261A patent/EP1859793B1/en active Active
- 2006-02-28 US US11/885,081 patent/US20090047278A1/en not_active Abandoned
- 2006-02-28 JP JP2007504857A patent/JPWO2006090930A1/ja active Pending
- 2006-02-28 ME MEP-2011-128A patent/ME01222B/me unknown
- 2006-02-28 ES ES06715261T patent/ES2362898T3/es active Active
- 2006-02-28 DE DE602006021401T patent/DE602006021401D1/de active Active
- 2006-02-28 WO PCT/JP2006/304218 patent/WO2006090930A1/ja active Application Filing
- 2006-02-28 CN CNA2006800137614A patent/CN101163468A/zh active Pending
- 2006-02-28 AU AU2006217692A patent/AU2006217692A1/en not_active Abandoned
- 2006-02-28 RS RS20110308A patent/RS51821B/en unknown
- 2006-02-28 PT PT06715261T patent/PT1859793E/pt unknown
-
2011
- 2011-05-11 HR HR20110349T patent/HRP20110349T1/hr unknown
- 2011-06-17 CY CY20111100583T patent/CY1111579T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006217692A1 (en) | 2006-08-31 |
| DE602006021401D1 (de) | 2011-06-01 |
| ES2362898T3 (es) | 2011-07-14 |
| JPWO2006090930A1 (ja) | 2008-07-24 |
| EP1859793A4 (en) | 2008-07-23 |
| EP1859793B1 (en) | 2011-04-20 |
| SI1859793T1 (sl) | 2011-08-31 |
| PT1859793E (pt) | 2011-07-05 |
| ME01222B (me) | 2013-06-20 |
| WO2006090930A1 (ja) | 2006-08-31 |
| CA2599115A1 (en) | 2006-08-31 |
| DK1859793T3 (da) | 2011-08-01 |
| US20090047278A1 (en) | 2009-02-19 |
| RS51821B (en) | 2012-02-29 |
| CY1111579T1 (el) | 2015-10-07 |
| KR20070108270A (ko) | 2007-11-08 |
| PL1859793T3 (pl) | 2011-09-30 |
| EP1859793A1 (en) | 2007-11-28 |
| CN101163468A (zh) | 2008-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110349T1 (hr) | Nova kombinacijska upotreba spoja sulfonamida u liječenju karcinoma | |
| ECSP088246A (es) | Nuevos derivados de benzotiazolona | |
| BRPI0408347B8 (pt) | derivados de pirimidina, seu uso, e composição e combinação farmacêuticas | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| BRPI0511933B8 (pt) | derivados de quinazolinona, seu uso e seu processo de preparação, e composição farmacêutica | |
| HN2002000319A (es) | Benzamida, heteroarilamida y amidas inversas | |
| UY27619A1 (es) | Ésteres hidroxamato del ácido n-(4-fenil sustituido)- antranílico | |
| BRPI0606112B8 (pt) | 3-hetero-aril-3-hidróxi-2-amino-propil aminas e compostos relacionados com atividade analgésica, uso dos mesmos e composição farmacêutica compreendendo os mesmos | |
| EA200700192A1 (ru) | Производные фталазина в качестве ингибиторов parp | |
| ECSP077271A (es) | Derivados de pirimidina | |
| BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
| UY27755A1 (es) | Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores. | |
| BRPI0507653A (pt) | derivados de imidazopiridina e imidazopiridina formulação farmacêutica compreendendo os mesmos e uso | |
| BRPI0514731A (pt) | derivados de pirimidina | |
| BRPI0715579A2 (pt) | "composto, composição farmacêutica e uso de um composto" | |
| BRPI0513901A (pt) | derivados de uréia cìclicos substituìdos, preparação dos mesmos e uso farmacêutico dos mesmos como inibidores de cinase | |
| ATE553106T1 (de) | Heteroarylpyrrolopyridinone als kinaseinhibitoren | |
| HN2003000196A (es) | Derivados de indolinfenilsulfonamida | |
| BRPI0508464B8 (pt) | sulfonilpirróis, composição farmacêutica compreendendo os mesmos e uso dos mesmos | |
| EA200700901A1 (ru) | Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии | |
| UY30748A1 (es) | Compuesto0s novedosos | |
| ECSP088288A (es) | DERIVADOS DE 7-(2-AMINO-1-HIDROXI-ETIL)-4-HIDROXIBENZOTIAZOL-2(3H)-ONA COMO AGONISTAS DE LOS ADRENOCEPTORES ß2 | |
| DK2041133T3 (da) | Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik | |
| UY30610A1 (es) | Moduladores de mglur5 | |
| BRPI0513944A (pt) | forma substancialmente pura de um composto de quinazolina, uso de um composto de quinazolina e composição |